top of page

Hymecromone clinical trial is cautiously positive

A very small (16 patients) phase 2a clinical trial for pulmonary hypertension associated with interstitial lung disease (PH-ILD) looked at whether hymecromone, a drug that might help blood vessels, had any promising effects.


Overall, the results weren't statistically significant, but half the patients treated with hymecromone improved their six-minute walk distance by 66m and had improved quality of life. Researchers concluded that a larger trial is warranted.


 
 
 

Recent Posts

Uric acid might cause PAH

Other studies have shown a relationship between high levels of uric acid and pulmonary arterial hypertension (PAH). This study looked at...

 
 
 

Comentários


PHA Canada

408 - 55 Water Street

Office 8928

Vancouver, BC, V6B 1A1

Email: info@phacanada.ca

Phone: 604-682-1036

Toll Free: 1-877-774-2226

  • Instagram
  • Facebook
  • X
  • LinkedIn
  • Youtube

Charitable Registration # 872050224RR0001

Copyright 2025 PHA CANADA, ALL RIGHTS RESERVED   |   Website created by Creativibe   |   Powered by raisin

bottom of page